Roche's "Pertuzumab" 3rd indication will be approved soon
- Categories:Company Dynamics
- Author:
- Origin:
- Time of issue:2019-04-13
- Views:4
(Summary description)A few days ago, nine departments including the Guangdong Health Commission, the Provincial Medical Insurance Bureau, and the Provincial Department of Finance jointly issued the "Key Points of Guangdong Province's Work on Correcting Unhealthy Trends in the Field of Pharmaceutical Purchase and Sales and Medical Services in 2019" to carry out special governance in key areas and strictly investigate false Invoicing, tax evasion and other illegal acts, severely crack down on illegal crimes such as commercial bribery and money laundering. (Cyber Blue)
| Negotiations for National Medical Insurance Consumables Start!
On November 20, the Hainan Provincial Pharmaceutical Centralized Procurement Service Platform announced the "Implementation Plan for the Management of High-Value Medical Consumables in Hainan Province", stating that it will gradually implement price negotiations for high-value medical consumables and medical insurance access to achieve "quantity for price." (Cyber Blue Equipment)
Part 2 Sankei Observation
| Proposed to introduce state-owned capital war investment, the actual controller of Laimei Pharmaceutical has changed
On November 25, Chongqing Laimei Pharmaceutical issued an announcement stating that Qiu Yu, the company’s controlling shareholder, negotiated with Chongqing Nan’an Urban Construction Development (Group) Co., Ltd. to terminate the "Strategic Cooperation Intention Agreement". At the same time, Laimei Pharmaceutical and Guangxi Wuzhou Zhongheng Group Co., Ltd. newly signed the "Strategic Cooperation Framework Agreement", entrusting the 22.71% of the company’s holdings with voting rights to Zhongheng Group for exercise. (Sina Pharmaceutical News)
Part 3 Medicine News
| The first domestic PD-L1 monoclonal antibody is about to be approved
On November 24, the domestic market application of AstraZeneca’s PD-L1 Durvalumab injection (Imfinzi) was under “approval” status. It is expected that it will soon be approved as the first domestically marketed PD-L1 monoclonal antibody drug for Treatment of inoperable stage III non-small cell lung cancer. (Insight database)
发送反馈
历史记录
A few days ago, nine departments including the Guangdong Health Commission, the Provincial Medical Insurance Bureau, and the Provincial Department of Finance jointly issued the "Key Points of Guangdong Province's Work on Correcting Unhealthy Trends in the
A few days ago, nine departments including the Guangdong Health Commission, the Provincial Medical Insurance Bureau, and the Provincial Department of Finance jointly issued the "Key Points of Guangdong Province's Work on Correcting Unhealthy Trends in the Field of Pharmaceutical Purchase and Sales and Medical Services in 2019" to carry out special governance in key areas and strictly investigate false Invoicing, tax evasion and other illegal acts, severely crack down on illegal crimes such as commercial bribery and money laundering. (Cyber Blue)
| Negotiations for National Medical Insurance Consumables Start!
A few days ago, nine departments including the Guangdong Health Commission, the Provincial Medical Insurance Bureau, and the Provincial Department of Finance jointly issued the "Key Points of Guangdong Province's Work on Correcting Unhealthy Trends in
Roche's "Pertuzumab" 3rd indication will be approved soon
(Summary description)A few days ago, nine departments including the Guangdong Health Commission, the Provincial Medical Insurance Bureau, and the Provincial Department of Finance jointly issued the "Key Points of Guangdong Province's Work on Correcting Unhealthy Trends in the Field of Pharmaceutical Purchase and Sales and Medical Services in 2019" to carry out special governance in key areas and strictly investigate false Invoicing, tax evasion and other illegal acts, severely crack down on illegal crimes such as commercial bribery and money laundering. (Cyber Blue)
| Negotiations for National Medical Insurance Consumables Start!
On November 20, the Hainan Provincial Pharmaceutical Centralized Procurement Service Platform announced the "Implementation Plan for the Management of High-Value Medical Consumables in Hainan Province", stating that it will gradually implement price negotiations for high-value medical consumables and medical insurance access to achieve "quantity for price." (Cyber Blue Equipment)
Part 2 Sankei Observation
| Proposed to introduce state-owned capital war investment, the actual controller of Laimei Pharmaceutical has changed
On November 25, Chongqing Laimei Pharmaceutical issued an announcement stating that Qiu Yu, the company’s controlling shareholder, negotiated with Chongqing Nan’an Urban Construction Development (Group) Co., Ltd. to terminate the "Strategic Cooperation Intention Agreement". At the same time, Laimei Pharmaceutical and Guangxi Wuzhou Zhongheng Group Co., Ltd. newly signed the "Strategic Cooperation Framework Agreement", entrusting the 22.71% of the company’s holdings with voting rights to Zhongheng Group for exercise. (Sina Pharmaceutical News)
Part 3 Medicine News
| The first domestic PD-L1 monoclonal antibody is about to be approved
On November 24, the domestic market application of AstraZeneca’s PD-L1 Durvalumab injection (Imfinzi) was under “approval” status. It is expected that it will soon be approved as the first domestically marketed PD-L1 monoclonal antibody drug for Treatment of inoperable stage III non-small cell lung cancer. (Insight database)
发送反馈
历史记录
- Categories:Company Dynamics
- Author:
- Origin:
- Time of issue:2019-04-13
- Views:4
A few days ago, nine departments including the Guangdong Health Commission, the Provincial Medical Insurance Bureau, and the Provincial Department of Finance jointly issued the "Key Points of Guangdong Province's Work on Correcting Unhealthy Trends in the Field of Pharmaceutical Purchase and Sales and Medical Services in 2019" to carry out special governance in key areas and strictly investigate false Invoicing, tax evasion and other illegal acts, severely crack down on illegal crimes such as commercial bribery and money laundering. (Cyber Blue)
| Negotiations for National Medical Insurance Consumables Start!
On November 20, the Hainan Provincial Pharmaceutical Centralized Procurement Service Platform announced the "Implementation Plan for the Management of High-Value Medical Consumables in Hainan Province", stating that it will gradually implement price negotiations for high-value medical consumables and medical insurance access to achieve "quantity for price." (Cyber Blue Equipment)
Part 2 Sankei Observation
| Proposed to introduce state-owned capital war investment, the actual controller of Laimei Pharmaceutical has changed
On November 25, Chongqing Laimei Pharmaceutical issued an announcement stating that Qiu Yu, the company’s controlling shareholder, negotiated with Chongqing Nan’an Urban Construction Development (Group) Co., Ltd. to terminate the "Strategic Cooperation Intention Agreement". At the same time, Laimei Pharmaceutical and Guangxi Wuzhou Zhongheng Group Co., Ltd. newly signed the "Strategic Cooperation Framework Agreement", entrusting the 22.71% of the company’s holdings with voting rights to Zhongheng Group for exercise. (Sina Pharmaceutical News)
Part 3 Medicine News
| The first domestic PD-L1 monoclonal antibody is about to be approved
On November 24, the domestic market application of AstraZeneca’s PD-L1 Durvalumab injection (Imfinzi) was under “approval” status. It is expected that it will soon be approved as the first domestically marketed PD-L1 monoclonal antibody drug for Treatment of inoperable stage III non-small cell lung cancer. (Insight database)
发送反馈
历史记录
Scan the QR code to read on your phone
CONTACT INFORMATION
Tel:+86-373-8968888
E-mail:kangminwc@163.com（Headquarters）
info@xxkmwc.com (International Division)
ONLINE MESSAGE
Copyright ©Xinxiang Kangmin Hygienic Materials Development CO.,LTD. 豫ICP备16017456号 Powered by: www.300.cn